Chemical inhibitors of BC026590 include a range of compounds that target various signaling pathways and molecular processes to achieve inhibition. Staurosporine, a well-known protein kinase inhibitor, can impede the phosphorylation essential for BC026590's activity, assuming phosphorylation is a key regulatory process for this protein. Similarly, the PI3K/Akt pathway, which is crucial for cell survival and proliferation, can be inhibited by compounds such as Wortmannin and LY294002. These inhibitors would prevent the downstream signaling required for BC026590's function if it is indeed a component of this pathway. Rapamycin, targeting the mTOR pathway, can also inhibit BC026590 by blocking the pathway's influence on cell growth and metabolism, provided BC026590 is regulated by mTOR. Furthermore, Triciribine, an Akt inhibitor, can obstruct the Akt-mediated signaling processes that might regulate BC026590.
Additional compounds such as PD98059 and U0126 inhibit the MAPK/ERK pathway, which would result in the functional inhibition of BC026590 if it is involved in this pathway. This could affect processes like cell division, differentiation, and response to growth factors. JNK inhibitor SP600125 can interfere with stress response signaling where BC026590 may play a role. SB203580's inhibition of p38 MAPK would affect BC026590 if it is involved in p38 MAPK-regulated processes such as inflammatory responses or cell differentiation. Inhibitors like Lestaurtinib and AG490, which target JAK2, can disrupt JAK/STAT signaling. BC026590 would be inhibited by these if it operates within or downstream of this pathway, which is implicated in numerous cellular functions, including proliferation and differentiation. Lastly, ZM447439 inhibits Aurora kinases, and if BC026590 is involved in cell cycle regulation or other processes reliant on Aurora kinase activity, this would result in its inhibition. Each of these chemical inhibitors disrupts specific cellular processes and pathways that are essential for BC026590's function, leading to its inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
As an inhibitor of protein kinases, Staurosporine can inhibit BC026590 by obstructing the phosphorylation process that might be essential for the protein's functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), and if BC026590 is involved in PI3K/Akt pathway signaling, its activity would be inhibited as a result of this blockade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that would lead to the functional inhibition of BC026590 if the protein operates within the PI3K/Akt signaling pathway by preventing downstream signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, and if BC026590 is involved in processes regulated by mTOR, the protein's activity would be inhibited as a result. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor that would inhibit BC026590 by stopping Akt-mediated processes if the protein's function is dependent on Akt signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
By selectively inhibiting MEK, PD98059 would inhibit the MAPK/ERK pathway, leading to the functional inhibition of BC026590 if it is part of this signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that would inhibit BC026590 by blocking the MAPK/ERK pathway, provided that BC026590 is involved in this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which would lead to the inhibition of BC026590 if the protein plays a role in JNK-mediated signaling pathways, particularly those involved in stress responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAPK and would functionally inhibit BC026590 if the protein is involved in p38 MAPK-regulated processes, such as inflammation or differentiation. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
By inhibiting JAK2, Lestaurtinib would inhibit BC026590 if the protein is part of JAK/STAT signaling, which is a pathway often implicated in cell proliferation and differentiation. | ||||||